Medical management of metabolic and cardiovascular complications after liver transplantation

Figure 1 Proposal of a treatment algorithm for diabetes mellitus type II in liver transplant recipients. GLP-1 RA: Glucagon-like peptide-1 receptor agonist; SGLT2 inhibitors: Sodium-glucose cotransporter type 2; DPP-4l: Inhibitors of dipeptidyl peptidase 4; NASH: Non-alcoholic steatohepatitis; NAFLD: Non-alcoholic fatty liver disease.

Figure 2 Proposal of a treatment algorithm for low-density lipoprotein cholesterol lowering strategy in liver transplant recipients. ¹Class of recommendation: IIa; level of evidence: B, according to 2019 ESC/EAS Guidelines for the management of dyslipidaemias[118]. ²Class of recommendation: IIb; level of evidence: C, according to 2019 ESC/EAS Guidelines for the management of dyslipidaemias[118]. LDL-C: Low-density lipoprotein cholesterol.